https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-02-15 / Cytotherapy 2017 04;19(4):500-513
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-02-15 / Cytotherapy 2017 04;19(4):500-5132017-02-15 00:00:002019-02-15 08:53:07Dendritic cell vaccination in combination with docetaxel for patients with metastatic castration-resistant prostate cancer: A randomized phase II study
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-02-01 / J. Immunother. 2017 Feb/Mar;40(2):71-76
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-02-01 / J. Immunother. 2017 Feb/Mar;40(2):71-762017-02-01 00:00:002019-02-15 08:52:03A Dendritic Cell Vaccine Combined With Radiotherapy Activates the Specific Immune Response in Patients With Esophageal Cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-01-27 / Crit. Rev. Oncol. Hematol. 2017 Mar;111:87-93
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-01-27 / Crit. Rev. Oncol. Hematol. 2017 Mar;111:87-932017-01-27 00:00:002019-02-15 08:51:20Immunotherapy for the treatment of multiple myeloma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-01-10 / Clin. Cancer Res. 2017 07;23(13):3352-3364
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-01-10 / Clin. Cancer Res. 2017 07;23(13):3352-33642017-01-10 00:00:002019-02-15 08:53:10Expression of CD14, IL10, and Tolerogenic Signature in Dendritic Cells Inversely Correlate with Clinical and Immunologic Response to TARP Vaccination in Prostate Cancer Patients
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-01-06 / Pharmacotherapy 2017 01;37(1):129-143
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-01-06 / Pharmacotherapy 2017 01;37(1):129-1432017-01-06 00:00:002019-02-15 08:51:21Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-01-01 / Adv Exp Med Biol 2017;1026:315-330
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-01-01 / Adv Exp Med Biol 2017;1026:315-3302017-01-01 00:00:002017-01-01 00:00:00Progress in Vaccine Therapies for Breast Cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-01-01 / Curr Cancer Drug Targets 2017;17(9):782-805
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-01-01 / Curr Cancer Drug Targets 2017;17(9):782-8052017-01-01 00:00:002019-02-15 08:36:11Targeting the Immune Niche within the Bone Marrow Microenvironment: The Rise of Immunotherapy in Multiple Myeloma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-12-27 / Cell Res. 2017 Jan;27(1):74-95
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-12-27 / Cell Res. 2017 Jan;27(1):74-952016-12-27 00:00:002019-02-15 08:45:14Dendritic cell-based immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-12-20 / J Immunother Cancer 2016;4:92
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-12-20 / J Immunother Cancer 2016;4:922016-12-20 00:00:002019-02-15 08:53:12The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-12-13 / Clin Cancer Res 2017 Jun;23(12):2961-2971
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-12-13 / Clin Cancer Res 2017 Jun;23(12):2961-29712016-12-13 00:00:002023-03-07 13:00:25Dendritic Cell Vaccination Enhances Immune Responses and Induces Regression of HER2 DCIS Independent of Route: Results of Randomized Selection Design Trial
